DLX 159
Alternative Names: DLX-159Latest Information Update: 15 Jan 2025
Price :
$50 *
At a glance
- Originator Delix Therapeutics
- Class Antidepressants; Small molecules
- Mechanism of Action Serotonin 2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Major depressive disorder; Psychiatric disorders
Most Recent Events
- 12 Dec 2024 Preclinical trials in Major depressive disorder in USA (PO)
- 12 Dec 2024 Preclinical trials in Psychiatric disorders in USA (PO)
- 12 Dec 2024 Efficacy, safety and pharmacokinets data from a preclinical studies in Major depressive disorder and Psychiatric disorders released by Delix Therapeutics